Kopran’s arm purchases API facility at Gujarat

15 May 2018 Evaluate

Kopran’s wholly owned subsidiary - Kopran Research Laboratories has purchased Maxheal Pharmaceuticals (India), an API facility at Panoli in the state of Gujarat on Slump Sale basis.

The acquired unit will be suitably upgraded and expanded. The expansion of the unit is expected to be completed by December, 2018 to launch new line of products.

Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.


Kopran Share Price

223.50 7.20 (3.33%)
23-Dec-2024 11:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1827.90
Dr. Reddys Lab 1351.20
Cipla 1489.40
Lupin 2188.50
Zydus Lifesciences 980.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.